You just read:

AbbVie reaches an agreement with the pan-Canadian Pharmaceutical Alliance (pCPA) for the Combination VENCLEXTA® With Rituximab as a Treatment for Patients With Chronic Lymphocytic Leukemia (CLL)

News provided by

AbbVie Canada

Dec 18, 2019, 14:56 ET